$-0.12 EPS Expected for Celldex Therapeutics, Inc. (CLDX)

October 13, 2018 - By Peter Kolinski

Analysts expect Celldex Therapeutics, Inc. (NASDAQ:CLDX) to report $-0.12 EPS on November, 6.They anticipate $0.02 EPS change or 14.29 % from last quarter’s $-0.14 EPS. After having $-0.11 EPS previously, Celldex Therapeutics, Inc.’s analysts see 9.09 % EPS growth. The stock increased 6.06% or $0.02 during the last trading session, reaching $0.42. About 1.03M shares traded. Celldex Therapeutics, Inc. (NASDAQ:CLDX) has declined 84.28% since October 13, 2017 and is downtrending. It has underperformed by 99.90% the S&P500.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Ratings Coverage

Among 2 analysts covering Celldex (NASDAQ:CLDX), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Celldex had 2 analyst reports since April 16, 2018 according to SRatingsIntel. Cowen & Co downgraded the stock to “Hold” rating in Monday, April 16 report. Cantor Fitzgerald maintained the shares of CLDX in report on Tuesday, April 17 with “Neutral” rating.

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company has market cap of $68.23 million. The Company’s drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; and Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer. It currently has negative earnings. It also develops earlier stage drug candidates in clinical development, including CDX-1401, an immunotherapeutic for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers.

Another recent and important Celldex Therapeutics, Inc. (NASDAQ:CLDX) news was published by Nasdaq.com which published an article titled: “Report: Developing Opportunities within Adamis Pharmaceuticals, Cass Information, Celldex Therapeutics, Par Pacific …” on October 09, 2018.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News